FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:2295-2301 November 25, 2004 Number 22 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Editorial by La Montagne, J. R. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background The loss of half the U.S. supply of influenza vaccine due to contamination has created a critical shortage. Dose-sparing strategies that use intradermal delivery of vaccines may be one approach to consider.

Methods We conducted a randomized, open-label trial outside the influenza season in 100 healthy adults 18 to 40 years of age to compare the immunogenicity and safety of intradermal immunization with influenza vaccine with standard intramuscular immunization. Subjects were randomly assigned to receive either a single intramuscular dose of 0.5 ml of trivalent influenza vaccine, containing at least 15 µg of hemagglutinin per strain, by means of a prefilled syringe or a single intradermal dose of 0.1 ml, containing at least 3 µg of hemagglutinin per strain, by means of a fine-gauge needle; both injections were in the deltoid region. Changes in the hemagglutination-inhibition (HAI) antibody titer were assessed by comparing geometric mean titers and fold increases relative to baseline values and by comparing changes in the seroconversion and seroprotection rates. Local and systemic adverse events were assessed after both types of vaccination.

Results Subjects who received an intradermal injection with one fifth the standard dose of influenza vaccine had increases in the geometric mean HAI titer by a factor of 15.2 for the H1N1 strain in the vaccine, 19.0 for the H3N2 strain, and 12.4 for the B strain on day 21, as compared with respective increases by a factor of 14.9, 7.1, and 15.3 for the intramuscular injection of the standard dose. Seroconversion and seroprotection rates were similar in the two groups on day 21, ranging from 66 to 82 percent and 84 to 100 percent, respectively. Local reactions were significantly more frequent among recipients of intradermal injections than among recipients of intramuscular injections, but such reactions were mild and transient.

Conclusions In this study of young adults, intradermal administration of one fifth the standard intramuscular dose of an influenza vaccine elicited immunogenicity that was similar to or better than that elicited by intramuscular injection. Intradermal administration could be used to expand the supplies of influenza vaccine, but further studies are needed before this strategy can be recommended for routine use.

Source Information

From Iomai, Gaithersburg, Md.

This article was published at www.nejm.org on November 4, 2004.

Address reprint requests to Dr. Glenn at Iomai, 20 Firstfield Rd., Suite 250, Gaithersburg, MD 20878, or at gglenn{at}iomai.com.

Full Text of this Article

Related Letters:

Intradermal Vaccination against Influenza
Weller T. H., Kilbourne E. D., Manian F. A., Belshe R. B., Treanor J., Dubin G., Glenn G. M., Kenney R. T.
Extract | Full Text | PDF  
N Engl J Med 2005; 352:1044-1046, Mar 10, 2005. Correspondence

This article has been cited by other articles:

• Andrianov, A. K., DeCollibus, D. P., Gillis, H. A., Kha, H. H., Marin, A., Prausnitz, M. R., Babiuk, L. A., Townsend, H., Mutwiri, G. (2009). Poly[di(carboxylatophenoxy)phosphazene] is a potent adjuvant for intradermal immunization. Proc. Natl. Acad. Sci. USA 106: 18936-18941 [Abstract] [Full Text]  
• Zhu, Q., Zarnitsyn, V. G., Ye, L., Wen, Z., Gao, Y., Pan, L., Skountzou, I., Gill, H. S., Prausnitz, M. R., Yang, C., Compans, R. W. (2009). Immunization by vaccine-coated microneedle arrays protects against lethal influenza virus challenge. Proc. Natl. Acad. Sci. USA 106: 7968-7973 [Abstract] [Full Text]  
• Huang, J., D'Souza, A. J., Alarcon, J. B., Mikszta, J. A., Ford, B. M., Ferriter, M. S., Evans, M., Stewart, T., Amemiya, K., Ulrich, R. G., Sullivan, V. J. (2009). Protective Immunity in Mice Achieved with Dry Powder Formulation and Alternative Delivery of Plague F1-V Vaccine. CVI 16: 719-725 [Abstract] [Full Text]  
• Falsey, A. R. (2008). Half-Dose Influenza Vaccine: Stretching the Supply or Wasting It?. Arch Intern Med 168: 2402-2403 [Full Text]  
• Engler, R. J. M., Nelson, M. R., Klote, M. M., VanRaden, M. J., Huang, C.-Y., Cox, N. J., Klimov, A., Keitel, W. A., Nichol, K. L., Carr, W. W., Treanor, J. J., for the Walter Reed Health Care System Influenza V, (2008). Half- vs Full-Dose Trivalent Inactivated Influenza Vaccine (2004-2005): Age, Dose, and Sex Effects on Immune Responses. Arch Intern Med 168: 2405-2414 [Abstract] [Full Text]  
• Vogt, A., Mahe, B., Costagliola, D., Bonduelle, O., Hadam, S., Schaefer, G., Schaefer, H., Katlama, C., Sterry, W., Autran, B., Blume-Peytavi, U., Combadiere, B. (2008). Transcutaneous Anti-Influenza Vaccination Promotes Both CD4 and CD8 T Cell Immune Responses in Humans. J. Immunol. 180: 1482-1489 [Abstract] [Full Text]  
• Hauge, S., Madhun, A., Cox, R. J., Haaheim, L. R. (2007). Quality and Kinetics of the Antibody Response in Mice after Three Different Low-Dose Influenza Virus Vaccination Strategies. CVI 14: 978-983 [Abstract] [Full Text]  
• Garg, S., Hoelscher, M., Belser, J. A., Wang, C., Jayashankar, L., Guo, Z., Durland, R. H., Katz, J. M., Sambhara, S. (2007). Needle-Free Skin Patch Delivery of a Vaccine for a Potentially Pandemic Influenza Virus Provides Protection against Lethal Challenge in Mice. CVI 14: 926-928 [Abstract] [Full Text]  
• Chiu, S. S., Peiris, J.S. M., Chan, K. H., Wong, W. H. S., Lau, Y. L. (2007). Immunogenicity and Safety of Intradermal Influenza Immunization at a Reduced Dose in Healthy Children. Pediatrics 119: 1076-1082 [Abstract] [Full Text]  
• Glenn, G. M., Villar, C. P., Flyer, D. C., Bourgeois, A. L., McKenzie, R., Lavker, R. M., Frech, S. A. (2007). Safety and Immunogenicity of an Enterotoxigenic Escherichia coli Vaccine Patch Containing Heat-Labile Toxin: Use of Skin Pretreatment To Disrupt the Stratum Corneum. Infect. Immun. 75: 2163-2170 [Abstract] [Full Text]  
• Alarcon, J. B., Hartley, A. W., Harvey, N. G., Mikszta, J. A. (2007). Preclinical Evaluation of Microneedle Technology for Intradermal Delivery of Influenza Vaccines. CVI 14: 375-381 [Abstract] [Full Text]  
• Mikszta, J. A., Dekker, J. P. III, Harvey, N. G., Dean, C. H., Brittingham, J. M., Huang, J., Sullivan, V. J., Dyas, B., Roy, C. J., Ulrich, R. G. (2006). Microneedle-Based Intradermal Delivery of the Anthrax Recombinant Protective Antigen Vaccine. Infect. Immun. 74: 6806-6810 [Abstract] [Full Text]  
• Kramer, J. S., Durham, C., Schroeder, T., Garrelts, J. C. (2006). Effectiveness of half-dose versus full-dose influenza vaccine in health care workers.. Am J Health Syst Pharm 63: 2111-2115 [Abstract] [Full Text]  
• Wyatt, K. N, Ryan, G. J, Sheerin, K. A (2006). Reduced-Dose Influenza Vaccine. The Annals of Pharmacotherapy 40: 1635-1639 [Abstract] [Full Text]  
• Zoeteweij, J. P., Epperson, D. E., Porter, J. D., Zhang, C. X., Frolova, O. Y., Constantinides, A. P., Fuhrmann, S. R., El-Amine, M., Tian, J.-H., Ellingsworth, L. R., Glenn, G. M. (2006). GM1 Binding-Deficient Exotoxin Is a Potent Noninflammatory Broad Spectrum Intradermal Immunoadjuvant. J. Immunol. 177: 1197-1207 [Abstract] [Full Text]  
• Khanlou, H., Sanchez, S., Babaie, M., Chien, C., Hamwi, G., Ricaurte, J.-C., Stein, T., Bhatti, L., Denouden, P., Farthing, C. (2006). The safety and efficacy of dose-sparing intradermal administration of influenza vaccine in human immunodeficiency virus-positive patients.. Arch Intern Med 166: 1417-1417 [Full Text]  
• Johansson, B. E., Brett, I. C., Focosi, D., Poland, G. A. (2006). An inactivated subvirion influenza A (H5N1) vaccine.. NEJM 354: 2724-2725 [Full Text]  
• Bertinetti, C., Zirlik, K., Heining-Mikesch, K., Ihorst, G., Dierbach, H., Waller, C. F., Veelken, H. (2006). Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression.. Cancer Res. 66: 4496-4502 [Abstract] [Full Text]  
• Treanor, J. J., Campbell, J. D., Zangwill, K. M., Rowe, T., Wolff, M. (2006). Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.. NEJM 354: 1343-1351 [Abstract] [Full Text]  
• Kling, C., Steinmann, J., Westphal, E., Magez, J., Kabelitz, D. (2006). Adverse effects of intradermal allogeneic lymphocyte immunotherapy: acute reactions and role of autoimmunity. Hum Reprod 21: 429-435 [Abstract] [Full Text]  
• Schwid, S. R., Decker, M. D., Lopez-Bresnahan, M., for the Rebif-Influenza Vaccine Study Investigator, (2005). Immune response to influenza vaccine is maintained in patients with multiple sclerosis receiving interferon beta-1a. Neurology 65: 1964-1966 [Abstract] [Full Text]  
• (2005). ADDITIONAL ARTICLES ABSTRACTED IN ACP JOURNAL CLUB. Evid. Based Med. 10: 94-94 [Full Text]  
• Weller, T. H., Kilbourne, E. D., Manian, F. A., Belshe, R. B., Treanor, J., Dubin, G., Glenn, G. M., Kenney, R. T. (2005). Intradermal Vaccination against Influenza. NEJM 352: 1044-1046 [Full Text]  
• Cosgrove, S. E., Fishman, N. O., Talbot, T. R., Woeltje, K. F., Schaffner, W., Fraser, V. J., McMillan, J. A., Perl, T. M. (2005). Strategies for Use of a Limited Influenza Vaccine Supply. JAMA 293: 229-232 [Full Text]  
• (2004). Low Doses of Intradermal Flu Vaccine Perform Well. JWatch General 2004: 1-1 [Full Text]  
• La Montagne, J. R., Fauci, A. S. (2004). Intradermal Influenza Vaccination -- Can Less Be More?. NEJM 351: 2330-2332 [Full Text]  
• (2004). Intradermal Immunization: An Approach to Maximizing the Flu Vaccine Supply. JWatch Infect. Diseases 2004: 1-1 [Full Text]